Cover
Vol. 7 No. 1 (2017)

Published: July 31, 2017

Pages: 1-6

Research Article

Role of Metformin on Recurrent Miscarriage and Other Pregnancy Complications in Women with Polycystic Ovarian Syndrome

Inaam Faisal Mohammed 1
1Department of Obstetrics and Gynecology-College of Medicine-University of Diyala - Diyala – IRAQ
History
  • Received: April 1, 2017
  • Available Online: July 1, 2017

Abstract

Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. Polycystic ovary syndrome signs and symptoms often begin soon after menarche. In some cases, PCOS develops later during the reproductive years, for instance, in response to substantial weight gain. The PCOS produces symptoms in about 5-10% of women of reproductive age(12-45 years) and it is one of the leading causes of female subfertility.Women with PCOS suffer not only from subfertility, but also from a high rate of early pregnancy loss. About 30-50% of clinically confirmed early pregnancy loss are associated with PCOS.In addition to early pregnancy loss, women with PCOS have increased risk of recurrent miscarriage ,which defined as 3 or more consecutive pregnancy loss before 20 week. Metformin hydrochloride, an insulin sensitizing agent, has been shown to have encouraging effects on several aspect of PCOS like insulin sensitivity, plasma glucose concentration & lipid profile.It is found that using Metformin during pregnancy in women with PCOS may reduce the pregnancy loss and also reduce the risk of gestational diabetes,intrauterine growth retardation(IUGR) & preterm labor. Aim of study: To evaluate the role of Metformin in women with recurrent miscarriage & its effect on other pregnancy complications in women with PCOS. Patients, Materials & Methods: A prospective study done at gynecology outpatient clinic of AL-Batool Teaching Hospital in Baquba-Diyala -Iraq, from September 2012 to September 2016. A total of 100 cases were studied, all have aconfirmed diagnosis of PCOS depending on the following criteria:1)Oligo or amenorrhea (8 or fewer cycles per a year) , 2) signs of hyperandrogenism 3)ultrasound features of PCOS.All should have history of 3 or more recurrent first trimester miscarriage & they were invistigated for other causes of recurrent miscarriage. All cases were followed before getting pregnant and received Metformin for enhancing fertility & when they become pregnant, they were divided into two groups: the 1st group stopped using Metformin once they get pregnant while the 2nd group continued to use Metformin in a dose of 500-1000mg per day throughout pregnancy .Both groups are followed to determine pregnancy outcome. Results: Patients who continued to receive Metformin during pregnancy had better pregnancy outcome regarding early pregnancy loss and recurrent miscarriage, gestational diabetes development, IUGR & preterm labor. Conclusions: Metformin use during pregnancy improve pregnancy outcome in patients with polycystic ovary syndrome.

Keywords

References

  1. Hoffman BL. Williams Gynecology. 2nd Ed. New York, N.Y.: The McGraw- Hill Companies; 2012. http://accessmedicine.com/resourceTOC.as px?resourceID=768. Accessed June 2, 2014
  2. Pratap Kumar, Kashif Khan .Effects of Metformin use in pregnant patients with polycystic ovary syndrome .J Hum Reprod Sci.2012; 5(2):166-169.
  3. Paulina A. Essah, Kai I. Cheang, John E. Nestler. The Pathophysiology of Miscarriage in Women with Polycystic Ovary Syndrome. Review and Proposed Hypothesis of Mechanisms Involved. HORMONES 2004; 3(4):221-227.
  4. Balen AH,Laven JSE,Tan SL&Dewailly D.Ultrasound assessment of polycystic ovary.Int Consensus Definition Human Reprod update.2003;9:505-14.
  5. E. Jauniaux, R. Farquharson, O. Christiansen and N. Exalto. Reply: Polycystic ovary-related miscarriage— should Metformin be proposed to such frustrated women Hum. Reprod. 2007; 22 (2): 623-624.
  6. Daniela J. Jakubowicz, Maria J. Iuorno, Salomon Jakubowicz, Katherine A. Roberts, and John E. Nestler. Effects of Metformin on Early Pregnancy Loss in the Polycystic Ovary Syndrome .The Journal of Clinical Endocrinology & Metabolism2001; 87(2).
  7. Breea Johnson PCOS and Miscarriage Rates.http://www.pullingdownthemoon.co m/blog/2010/september/pcos-and- miscarriage-rates.aspx
  8. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls.Obstet Gynecol Surv.2004; 59:141- 245.
  9. Gray RH, Wu LY. Subfertility and risk of spontaneous abortion. Am J Public Health.2000; 90:1452–1454.
  10. Billa E,Kapolla N,Nicopoulou SC,Venaki E,Milingos S, et al.Metformin administration was associated with a modification of LH,prolactin and insulin secreation dynamics in women with polycystic ovarian syndrome.Gynecol Endocrinol.2009;25:427-34.
  11. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with Metformin. Hum Reprod. 2002; 17:2858–64.
  12. Nawaz FH, Khalid R, Naru T, Rizvi J. Does continuous use of Metformin throughout pregnancy improve pregnancy outcomes in women with polycystic ovarian syndrome? J Obstet Gynaecol Res. 2008; 34:832–7.
  13. Lilja AE, Mathiesen ER. Polycystic ovary syndrome and Metformin in pregnancy. Acta Obstet Gynecol Scand. 2006; 85:861–8.
  14. Palomba S,Falbo A,Orio F Jr,Russo T,Tolino A,Zullo F.Metformin hydrochloride and recurrent miscarriage in women with polycystic ovary syndtom.Fertil Steril.2006,85(5):1511.e3- 5.
  15. Jakubowicz D J,Seppala M, Jakubowicz S,Rodriguez-Armas O,Rivas- Santiago A,Koistinen H, Koistinen R,Nestler JE.Insulin reduction with Metformin increases luteal phase serum glycodelin and insulin-like growth factor- binding protein1 concentration and enhances uterine vascularity and blood flow in polycystic ovary syndrome.J Clin Endocrinol Metab.2001,86:1126-274.
  16. Blton AE, Pockley AG, Clough KJ, Mowles EA, Stoker RJ, Westwood OM.Chapman MG.Identification of placental protein 14 as an immunosuppressive factor in human reproduction.Lancent.198, 1:593-595.
  17. Gludice LC,Mark SP,Irwin JC.Paracrine action of insulin –like growth factors and IGF binding protein-1 in non- pregnant human endometrium and at the decidual-trophoblast interface.J Reprod Immunol.1998,39:133-148.
  18. Okamoto N,Uchida A,Takakura K,Kariya Y,Kanzaki H,Riittinen L,Koistinen R,Seppala M,Mori T.Suppression by human placental protein 14 of natural killer cell activity.AM J Reprod Immunol.1991,26:137-142.
  19. Jones JI,Gockerman A,Busby WHJ,Wright G,Clemmons DR.Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp 6 sequence.Proc Natl Acad Sci USA.1993,90:10553-10557.
  20. Sarlis NJ, Weil SJ, Nelson LM.Adminstration of Metformin to a diabetic woman with extreme hyperandrogenemia of nontumoral origin: management of infertility and prevention of inadvertent masculinization of a female fetus.J Clin Endocrinol Metab.1999, 84:1510-1512.
  21. Glueck CJ,Wang P,Fontaine RN,Sieve-Smith L,Tracy T,Moore SK.Plasminogen activator inhibitor activity:an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome.Metabolism.1999,48:1589- 1595.
  22. Gris JC,Neveu S,Mares P,Biron C,Hedon B,Schved JF.Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology.J Lab Clin Med1993,122:606-6015.
  23. Khatt ab S,Mohsen IA,Aboulfoutouh I,Ashmawi HS,Mohsen MN,Van Wely M,et al.Can Metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome.?Prospective cohort study.Gynecol Endorinol.2011; 27:789-9.
  24. Balani J, Hyer SL, Rodin DA, Shehata H.Pregnancy outcomes in women with gestational diabetes treated with Metformin or insulin: A case-control study.Diabet Med.2009; 26:798-802.
  25. Velaza EM, Mendoza S, Hamer T, Sossa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.Metabolism.1994; 43:647- 54.